Company intelligence / Profile preview

RhyGaze

Ownership: Private
Development stage: Preclinical

Overview

RhyGaze is developing a novel gene therapy that targets cone cells to restore vision in patients with blinding retinal diseases. The therapy delivers a new light-sensor gene specifically to cone cells that have lost light sensitivity, repairing their ability to detect light. The company has secured Series A financing to conduct formal pharmacology and toxicology testing, a non-interventional observational study, and prepare for first-in-human clinical trials.

Therapeutic areas: Ophthalmology
Modalities: Gene therapy
Industry: Biotech

Partnerships

Institute of Molecular and Clinical Ophthalmology Basel (IOB)

Beyond the preview

Go deeper on RhyGaze.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RhyGaze.

Explore the full profile